Outlook Therapeutics, Inc.(OTLK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

OTLK Outlook Therapeutics, Inc.

交易中 10-14 13:54:58 EDT

0.5135

-0.0503

-8.92%

最高0.5651	最低0.5011	成交量543.39万
今开0.5601	昨收0.5638	日振幅11.35%
总市值1.25亿	流通市值1.02亿	总股本2.43亿
成交额284.75万	换手率2.74%	流通股本1.98亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"OTLK","market":"US","secType":"STK","nameCN":"Outlook Therapeutics, Inc.","latestPrice":0.5135,"timestamp":1792000494230,"preClose":0.5638,"halted":0,"volume":5433860,"delay":0,"changeRate":-0.08921603405462933,"floatShares":198000000,"shares":243000000,"eps":-0.747935,"marketStatus":"交易中","change":-0.0503,"latestTime":"10-14 13:54:58 EDT","open":0.5601,"high":0.5651,"low":0.5011,"amount":2847517.6102919998,"amplitude":0.113515,"askPrice":0.5135,"askSize":2200,"bidPrice":0.5134,"bidSize":599,"shortable":0,"etf":0,"ttmEps":-0.747935,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1792008000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.5638,"preHourTrading":{"tag":"盘前","latestPrice":0.566,"preClose":0.5638,"latestTime":"09:29 EDT","volume":35810,"amount":20467.16969,"timestamp":1791984599106,"change":0.0022,"changeRate":0.003902,"amplitude":0.034764},"postHourTrading":{"tag":"盘后","latestPrice":0.56,"preClose":0.5638,"latestTime":"19:48 EDT","volume":42504,"amount":23934.2347,"timestamp":1791935302933,"change":-0.0038,"changeRate":-0.00674,"amplitude":0.035296},"volumeRatio":2.28698,"impliedVol":1.5446,"impliedVolPercentile":0.4343},"requestUrl":"/m/hq/s/OTLK","defaultTab":"news","newsList":[{"id":"1195813570","title":"Outlook Therapeutics任命Kevin Lundquist为首席财务官 备战Lytenava™美国商业化上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1195813570","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195813570?lang=zh_cn&edition=full","pubTime":"2026-08-28 04:06","pubTimestamp":1787861213,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc.宣布任命Kevin Lundquist担任公司首席财务官一职。此举正值该公司紧锣密鼓筹备Lytenava在美国市场的商业化推出之际。随着Lytenava上市准备的全面推进，Lundquist的财务专长与战略视野预计将为公司带来新的增长动能。据悉，Lundquist将全面负责公司的财务战略、资本配置及投资者关系等核心职能，直接助力Outlook Therapeutics在眼科治疗领域的商业化进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152377290","title":"Outlook Therapeutics公布2026财年第三季度财务业绩，并发布公司动态，重点强调FDA批准Lytenava™","url":"https://stock-news.laohu8.com/highlight/detail?id=1152377290","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152377290?lang=zh_cn&edition=full","pubTime":"2026-08-14 19:17","pubTimestamp":1786706230,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc. 发布了2026财年第三季度的财务报告，同时更新了公司业务进展，其中核心亮点是Lytenava™已获得美国食品药品监督管理局（FDA）的批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173205729","title":"Outlook Therapeutics 终止与H.C. Wainwright的ATM发行协议，撤回2026年5月13日招股书补充文件——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1173205729","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173205729?lang=zh_cn&edition=full","pubTime":"2026-08-13 04:04","pubTimestamp":1786565050,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc.宣布，已正式终止其与H.C. Wainwright & Co., LLC签订的ATM发行协议。这一决定，伴随着对2026年5月13日相关招股说明书补充文件的撤回，已在最新提交给美国证券交易委员会的文件中明确披露。然而，Outlook Therapeutics并未在简短的文件中透露终止背后的具体原因，也未说明后续是否会寻求其他替代性融资渠道。回溯来看，这份最初于2026年5月13日生效的招股书补充文件，曾为公司与H.C. Wainwright的合作设定了明确的框架。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136247811","title":"Outlook Therapeutics 募资投向：助力Lytenava美国上市、补充运营资金及企业一般用途","url":"https://stock-news.laohu8.com/highlight/detail?id=1136247811","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136247811?lang=zh_cn&edition=full","pubTime":"2026-08-13 04:02","pubTimestamp":1786564929,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics 宣布，其最新融资所得将用于支持核心产品Lytenava在美国的上市推广，同时补充公司运营资本，并满足企业日常运营及一般性开支需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104353517","title":"Outlook Therapeutics 宣布 Lytenava™ 获 FDA 批准：成为首个且唯一用于治疗湿性 AMD 的眼用贝伐珠单抗","url":"https://stock-news.laohu8.com/highlight/detail?id=1104353517","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104353517?lang=zh_cn&edition=full","pubTime":"2026-07-25 02:41","pubTimestamp":1784918495,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics 正式宣布，其药物 Lytenava™ 已获得美国食品药品监督管理局（FDA）批准。这是首款、也是唯一一款获 FDA 许可、专用于治疗湿性年龄相关性黄斑变性（湿性 AMD）的眼用贝伐珠单抗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166622993","title":"Outlook Therapeutics Inc：依据生物制品价格竞争与创新法案，预计享有12年市场独占期","url":"https://stock-news.laohu8.com/highlight/detail?id=1166622993","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166622993?lang=zh_cn&edition=full","pubTime":"2026-07-25 02:41","pubTimestamp":1784918469,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Inc：依据《生物制品价格竞争与创新法案》，该公司预计将获得长达12年的市场独占权。法案的庇护，意味着其产品在特定领域内将独享竞争壁垒，免受仿制生物制品的直接冲击。在专利丛林与法规迷宫中，如此明确的独占期，无疑为投资者与研发团队注入了一剂强心针。Outlook Therapeutics正站在这一历史性机遇的十字路口，其未来走向，值得密切追踪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134726052","title":"Outlook Therapeutics宣布FDA接受其重新提交的Ons-5010/Lytenava™生物制剂许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1134726052","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134726052?lang=zh_cn&edition=full","pubTime":"2026-06-16 20:02","pubTimestamp":1781611349,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc. 宣布，美国食品药品监督管理局已正式接受其针对湿性年龄相关性黄斑变性治疗药物Ons-5010/Lytenava™（Bevacizumab-Vikg）重新提交的生物制剂许可申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129840263","title":"Outlook Therapeutics宣布重新向美国FDA提交Ons-5010/Lytenava™ (Bevacizumab-Vikg)的生物制品许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1129840263","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129840263?lang=zh_cn&edition=full","pubTime":"2026-06-01 20:47","pubTimestamp":1780318050,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc. 已正式宣布，公司已重新向美国食品药品监督管理局（FDA）提交了其候选药物Ons-5010/Lytenava™ (贝伐珠单抗-Vikg)的生物制品许可申请（BLA）。此举标志着该药物在寻求监管批准以治疗湿性年龄相关性黄斑变性（wet AMD）的进程中迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123921412","title":"Outlook Therapeutics宣布根据纳斯达克规则完成500万美元市场价注册直接发行定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1123921412","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123921412?lang=zh_cn&edition=full","pubTime":"2026-05-29 04:00","pubTimestamp":1779998412,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc. 已公布其根据纳斯达克市场规则进行的注册直接发行的定价细节。此次发行总规模为500万美元，发行价格严格遵循\"按市价\"原则确定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197521520","title":"Outlook Therapeutics完成FDA争议解决会议，Ons-5010最终裁决预计2026年5月揭晓","url":"https://stock-news.laohu8.com/highlight/detail?id=1197521520","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197521520?lang=zh_cn&edition=full","pubTime":"2026-05-16 04:06","pubTimestamp":1778875582,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc. 已成功完成针对其候选药物Ons-5010的美国食品药品监督管理局（FDA）争议解决会议。公司正积极推动该药物的审批进程，最终监管决定预计将于2026年5月公布。这一关键步骤标志着Ons-5010在寻求上市批准的道路上取得了重要进展，为后续的潜在商业化铺平了道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194394923","title":"Outlook Therapeutics公布2026财年第二季度财务业绩并发布公司最新动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1194394923","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194394923?lang=zh_cn&edition=full","pubTime":"2026-05-16 04:06","pubTimestamp":1778875575,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc. 已正式发布其2026财年第二季度的财务报告，同时向市场提供了公司业务进展的最新情况。此次披露涵盖了公司在该财季内的关键财务数据与运营更新，旨在让投资者全面了解公司当前的发展状况与未来规划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108219090","title":"Outlook Therapeutics与H.C. Wainwright签订ATM发行协议，融资额最高可达1亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1108219090","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108219090?lang=zh_cn&edition=full","pubTime":"2026-05-14 04:44","pubTimestamp":1778705058,"startTime":"0","endTime":"0","summary":"根据向美国证券交易委员会提交的文件显示，生物制药公司Outlook Therapeutics, Inc.已与投资银行H.C. Wainwright & Co.签订了一项市场股票发行协议。根据该协议条款，Outlook Therapeutics将有权在特定时期内，通过H.C. Wainwright作为销售代理，不定期地发行和出售其普通股股票，以此筹集资金。此次ATM发行的总融资额度最高可达1亿美元。市场股票发行是一种灵活的融资工具，允许上市公司根据市场条件和自身资金需求，在既定额度内按现行市价向公众投资者出售新发行的股票。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182483377","title":"Outlook Therapeutics宣布500万美元纳斯达克规则下市价定价注册直接发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1182483377","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182483377?lang=zh_cn&edition=full","pubTime":"2026-04-22 20:30","pubTimestamp":1776861036,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc.  今日披露了一项重要融资安排。该公司已达成协议，将通过注册直接发行的方式募集500万美元资金。此次发行定价严格遵循纳斯达克市场的相关规定，采用市价定价机制。这项融资举措标志着Outlook Therapeutics在资本运作方面迈出关键一步。根据纳斯达克规则，此次发行符合市场化定价原则。此次融资所得将用于推进公司核心管线的临床开发及一般营运资金需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107650089","title":"Outlook Therapeutics完成与FDA就ONS-5010/Lytenava™（贝伐珠单抗-Vikg）的联邦争议解决会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1107650089","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107650089?lang=zh_cn&edition=full","pubTime":"2026-04-21 21:06","pubTimestamp":1776776777,"startTime":"0","endTime":"0","summary":"生物制药公司Outlook Therapeutics, Inc. (OTLK) 已顺利完成与美国食品药品监督管理局（FDA）针对眼科药物ONS-5010/Lytenava™（贝伐珠单抗-Vikg）的联邦争议解决（FDR）会议。此次关键性会议标志着该药物在寻求监管批准路径上的一个重要里程碑。公司正积极推动这一潜在疗法，旨在为湿性年龄相关性黄斑变性（wet AMD）患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518042662","title":"Outlook Therapeutics, Inc.盘中异动 下午盘股价大跌5.34%报1.41美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518042662","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518042662?lang=zh_cn&edition=full","pubTime":"2025-03-11 02:56","pubTimestamp":1741633004,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日02时56分，Outlook Therapeutics, Inc.股票出现异动，股价急速下跌5.34%。Outlook Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.47%。其相关个股中，Aeon Biopharma, Inc.、Mineralys Therapeutics, Inc.、Checkpoint Therapeutics, Inc.涨幅较大，Aeon Biopharma, Inc.、Biodexa Pharmaceuticals Plc、Scisparc Ltd.较为活跃，换手率分别为6148.90%、3854.04%、1014.79%，振幅较大的相关个股有Aeon Biopharma, Inc.、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Biodexa Pharmaceuticals Plc，振幅分别为90.44%、88.14%、59.34%。Outlook Therapeutics, Inc.公司简介：Outlook Therapeutics Inc 是一家临床阶段生物制药公司，专注于开发和商业化 ONS-5010，这是一种用于各种眼科适应症的单克隆抗体 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311025644a26a9d94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311025644a26a9d94&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517698565","title":"Outlook Therapeutics, Inc.盘中异动 下午盘股价大涨5.28%报1.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517698565","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517698565?lang=zh_cn&edition=full","pubTime":"2025-03-05 04:19","pubTimestamp":1741119563,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日04时19分，Outlook Therapeutics, Inc.股票出现异动，股价急速上涨5.28%。Outlook Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.09%。Outlook Therapeutics, Inc.公司简介：Outlook Therapeutics Inc 是一家临床阶段生物制药公司，专注于开发和商业化 ONS-5010，这是一种用于各种眼科适应症的单克隆抗体 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305041923a25f65a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305041923a25f65a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516688296","title":"Outlook Therapeutics, Inc.盘中异动 下午盘股价大跌5.00%报1.43美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516688296","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516688296?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:02","pubTimestamp":1741032163,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时02分，Outlook Therapeutics, Inc.股票出现异动，股价大幅跳水5.00%。Outlook Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.20%。其相关个股中，Bioxcel Therapeutics, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Biocardia, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Allarity Therapeutics, Inc.、Entero Therapeutics Inc.较为活跃，换手率分别为4576.31%、211.77%、182.41%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.，振幅分别为206.20%、119.50%、70.53%。Outlook Therapeutics, Inc.公司简介：Outlook Therapeutics Inc 是一家临床阶段生物制药公司，专注于开发和商业化 ONS-5010，这是一种用于各种眼科适应症的单克隆抗体 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304040243abe68edc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304040243abe68edc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514566375","title":"Outlook Therapeutics, Inc.盘中异动 早盘快速拉升5.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514566375","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514566375?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:53","pubTimestamp":1740754380,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时53分，Outlook Therapeutics, Inc.股票出现异动，股价急速上涨5.80%。Outlook Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.28%。Outlook Therapeutics, Inc.公司简介：Outlook Therapeutics Inc 是一家临床阶段生物制药公司，专注于开发和商业化 ONS-5010，这是一种用于各种眼科适应症的单克隆抗体 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228225300abe0f06f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228225300abe0f06f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514045867","title":"Outlook Therapeutics, Inc.盘中异动 下午盘股价大跌5.23%报1.44美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514045867","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514045867?lang=zh_cn&edition=full","pubTime":"2025-02-26 03:28","pubTimestamp":1740511706,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日03时28分，Outlook Therapeutics, Inc.股票出现波动，股价急速跳水5.23%。Outlook Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.18%。Outlook Therapeutics, Inc.公司简介：Outlook Therapeutics Inc 是一家临床阶段生物制药公司，专注于开发和商业化 ONS-5010，这是一种用于各种眼科适应症的单克隆抗体 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226032826abdcc28f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226032826abdcc28f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513214988","title":"Outlook Therapeutics, Inc.盘中异动 股价大跌5.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513214988","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513214988?lang=zh_cn&edition=full","pubTime":"2025-02-22 04:07","pubTimestamp":1740168426,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日04时07分，Outlook Therapeutics, Inc.股票出现异动，股价急速下挫5.43%。Outlook Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.48%。其相关个股中，Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Invivyd, Inc.、Moolec Science Sa C/Wts 涨幅较大，Aditxt, Inc.、Nkgen Biotech, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为316.92%、251.10%、138.24%，振幅较大的相关个股有Osr Holdings, Inc.、Invivyd, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028，振幅分别为76.52%、70.25%、61.26%。Outlook Therapeutics, Inc.公司简介：Outlook Therapeutics Inc 是一家临床阶段生物制药公司，专注于开发和商业化 ONS-5010，这是一种用于各种眼科适应症的单克隆抗体 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222040707a24ef57e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222040707a24ef57e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OTLK","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.outlooktherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0143},{"period":"1month","weight":-0.1458},{"period":"3month","weight":-0.6386},{"period":"6month","weight":1.0851},{"period":"1year","weight":-0.5696},{"period":"ytd","weight":-0.6432}],"compareEarnings":[{"period":"1week","weight":-0.0014},{"period":"1month","weight":0.018},{"period":"3month","weight":0.0307},{"period":"6month","weight":0.1088},{"period":"1year","weight":0.1734},{"period":"ytd","weight":0.1409}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Outlook Therapeutics, Inc.于2010年1月5日在新泽西州注册成立。该公司是一家生物制药公司，在欧盟或欧盟、英国或英国率先获得ONS-5010/LYTENAVA（贝伐珠单抗-gamma）眼科制剂上市许可，用于治疗湿性年龄相关性黄斑变性，或湿性AMD。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.033268},{"month":2,"riseRate":0.4,"avgChangeRate":0.1402},{"month":3,"riseRate":0.3,"avgChangeRate":-0.095662},{"month":4,"riseRate":0.5,"avgChangeRate":-0.0707},{"month":5,"riseRate":0.7,"avgChangeRate":0.330761},{"month":6,"riseRate":0.4,"avgChangeRate":0.075556},{"month":7,"riseRate":0.545455,"avgChangeRate":0.003223},{"month":8,"riseRate":0.272727,"avgChangeRate":-0.194294},{"month":9,"riseRate":0.454545,"avgChangeRate":0.035752},{"month":10,"riseRate":0.454545,"avgChangeRate":0.159365},{"month":11,"riseRate":0.2,"avgChangeRate":-0.102562},{"month":12,"riseRate":0.3,"avgChangeRate":-0.107149}],"exchange":"NASDAQ","name":"Outlook Therapeutics, Inc.","nameEN":"Outlook Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Outlook Therapeutics, Inc.(OTLK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Outlook Therapeutics, Inc.(OTLK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Outlook Therapeutics, Inc.,OTLK,Outlook Therapeutics, Inc.股票,Outlook Therapeutics, Inc.股票老虎,Outlook Therapeutics, Inc.股票老虎国际,Outlook Therapeutics, Inc.行情,Outlook Therapeutics, Inc.股票行情,Outlook Therapeutics, Inc.股价,Outlook Therapeutics, Inc.股市,Outlook Therapeutics, Inc.股票价格,Outlook Therapeutics, Inc.股票交易,Outlook Therapeutics, Inc.股票购买,Outlook Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Outlook Therapeutics, Inc.(OTLK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Outlook Therapeutics, Inc.(OTLK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}